Markets:

Overview

News

Currencies

International

Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

17.62 +0.22 (+1.26%)

Streaming Delayed Price Updated: 10:22 AM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Via The Motley Fool

Topics Regulatory Compliance

Eton Pharma (ETON) Q3 2025 Earnings Transcript ↗

November 09, 2025

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Via The Motley Fool

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast ↗

May 12, 2025

Via Benzinga

The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts ↗

January 08, 2025

Via Benzinga

Analyst Expectations For Eton Pharmaceuticals's Future ↗

November 13, 2024

Via Benzinga

ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss ↗

November 06, 2025

Eton Pharmaceuticals Q3 2025 results: A mixed quarter with a 7.6% revenue beat but a miss on earnings per share.

Via Chartmill

Eton (ETON) Q2 Revenue Jumps 108% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue ↗

May 29, 2025

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.

Via Benzinga

A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts ↗

May 14, 2025

Via Benzinga

Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula ↗

April 25, 2025

A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing?

Via Chartmill

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Outlook For Eton Pharmaceuticals ↗

November 11, 2024

Via Benzinga

Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know ↗

October 28, 2024

Via Benzinga

Recap: Eton Pharmaceuticals Q4 Earnings ↗

March 14, 2024

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

5 Analysts Assess Eton Pharmaceuticals: What You Need To Know ↗

March 19, 2025

Via Benzinga

Earnings Scheduled For March 18, 2025 ↗

March 18, 2025

Via Benzinga

Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch ↗

March 14, 2025

Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 14, 2025

Via Benzinga

Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 10, 2025

Via Benzinga

3 Stocks Insiders Are Buying Heavily In October 2024, And Why ↗

October 09, 2024

Should investors add these stocks on their watchlist? Insider buys suggest so.

Via Talk Markets

Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday ↗

October 04, 2024

Via Benzinga

ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 22, 2024

Via Benzinga

ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 ↗

March 14, 2024

ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.